Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
AstraZeneca (AZN) Share Price & Analysis
311 Followers
AZN Stock Chart & Stats
Day’s Range12,318p - 12,432p
52-Week Range― - ―
Previous Close12,344p
Volume79.77K
Average Volume (3M)N/A
Market Cap
£191.76B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Jul 25, 2024EPS Estimate
£1.61Last Dividend Ex-Date
Feb 22, 2024Dividend Yield1.85%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
11,955.67pPrice Target Upside-3.39% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering18
AstraZeneca News
PremiumCompany Announcements
AstraZeneca Expands with Cellectis Equity Investment
PremiumCompany Announcements
AstraZeneca’s Calquence Sets New Standard in Lymphoma CareBulls Say, Bears Say
Bulls Say
Drug EfficacyBaxdrostat shows promising Phase III results in resistant hypertension, with expectations of superior efficacy compared to competitors.
Market OpportunityThe potential of Camizestrant to increase SERD mechanism usage and replace current treatments indicates an opportunity for market growth.
Product PipelineThe company's robust product pipeline and positive data points contribute to the analyst's BUY rating and a price objective that suggests a significant upside from the current price.
Bears Say
Guidance ConcernsThe only disappointment is the lack of the guidance upgrade given current implied guidance is below consensus.
Margin And Earnings IssuesConcerns regarding mid-term margin and recent quarterly earnings misses are central to the bear case.
Product Development DelaysEplontersen Phase III read shift to FY26, indicating a longer timeline for potential revenue from this asset.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.18% Insiders
14.33% Mutual Funds
8.15% Other Institutional Investors
77.35% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
Currently, no data Available
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Jul 25, 2024 which is in 75 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Apr 25, 2024. The company reported 1.65p earnings per share for the quarter, beating the consensus estimate of 1.53p by 0.119p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Overvalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 156p which represents an annual dividend yield of 1.85%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is £1.61.
How many shares outstanding does AstraZeneca PLC have?
Currently, no data Available
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.65p in its last earnings report, beating expectations of 1.53p. Following the earnings report the stock price went up 5.937%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
11,955.67p (-3.39% Downside)
11,955.67p (-3.39% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.98%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
3.55%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZN Stock 12 Month Forecast
Average Price Target
11,955.67p
▼(-3.39% Downside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
19/22 ratings generated profit
1 Year Average Return
+13.96%
reiterated a buy rating 3 days ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 86.36% of your transactions generating a profit, with an average return of +13.96% per trade.
---